Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335660 | 0.83 | — | — | |
| SCHEMBL11838438 | 0.82 | MEN1 (0.42) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL6138297 | 0.82 | MEN1 (0.34) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL19358804 | 0.80 | HCN1 (0.30) | OPRM1OPRL1OPRK1 | |
| SCHEMBL6698499 | 0.80 | KDM4E (0.31) | MEN1KMT2A | |
| SCHEMBL17431790 | 0.80 | MEN1 (0.40) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL11315166 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL16757277 | 0.78 | MEN1 (0.39) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL9562288 | 0.77 | CHRNA7 (0.36) | OPRM1OPRL1OPRK1MEN1KMT2A | |
| SCHEMBL25417165 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026335-B2 | Melanocortin receptor ligands | THE PROCTER & GAMBLE CO. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050171158-A1 | Melanocortin receptor ligands | EBETINO FRANK H (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1499588-A1 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236230-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003093234-A1 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171158-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | OPRM1 16/4885OPRL1 12/4885OPRK1 58/4885 |
| US-20030236230-A1 | Melanocortin receptor ligands | MC1R, MC4R, MC5R | OPRM1 15/4885OPRL1 12/4885OPRK1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.